Financial Instruments and Fair Value Measurements (Narrative) (Details) CAD in Millions, $ in Millions	3 Months Ended	9 Months Ended
	Jun. 26, 2015 USD ($)	Jun. 26, 2015 USD ($)	Jun. 26, 2015 CAD	Jun. 26, 2015 CAD	Sep. 26, 2014 USD ($)	Aug. 14, 2014 USD ($)	Aug. 13, 2014	Apr. 30, 2013	Oct. 01, 2012 USD ($)
CNS Therapeutics, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration									$ 6.9
Maximum contingent payments for acquisition									$ 9.0
Discount rate		1.00%	1.00%
Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent liability						$ 195.4
Secured Debt | 2.85% Term Loan | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	2.85%	2.85%		2.85%
Secured Debt | 4.00% Term Loan | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.00%	4.00%		4.00%
Debentures | 8.00% Debenture | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	8.00%	8.00%		8.00%
Debentures | 9.50% Debenture | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	9.50%	9.50%		9.50%
Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate								3.50%
Senior Notes | 3.50% Senior Notes | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	3.50%	3.50%		3.50%
Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate								4.75%
Senior Notes | 4.75% Senior Notes | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.75%	4.75%		4.75%
Senior Notes | 5.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate							5.75%
Senior Notes | 5.75% Senior Notes | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	5.75%	5.75%		5.75%
Senior Notes | 4.88% Senior Notes | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.875%	4.875%		4.875%
Senior Notes | 5.50% Senior Notes | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	5.50%	5.50%		5.50%
Other Assets | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 91.7	$ 91.7			$ 69.8
Other Assets | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash surrender value of life insurance	68.4	68.4			$ 69.0
Recurring | Level 3 | CNS Therapeutics, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	7.2	7.2
Recurring | Level 3 | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent liability	168.2	$ 168.2
Synacthen | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate		4.70%	4.70%
Milestone Payments	$ 25.0
Milestone payment, upon FDA approval		$ 25.0
Milestone payments, maximum amount		190.0
Synacthen | Fiscal 2015 and 2016 | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone Payments		25.0
Synacthen | Fiscal 2015 and 2016 | Prepaid expenses and other current assets | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone Payments		25.0
Synacthen | Subsequent to Fiscal 2016 | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone Payments		$ 25.0
BioVectra, Inc. | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate		1.30%	1.30%
Fair value of contingent liability | CAD				CAD 45.0
Payments | CAD			CAD 5.0
Business Combination, Contingent Consideration, Potential Payment | CAD				CAD 40.0